Cognitive Rehabilitation for Post-COVID Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method to assist individuals experiencing cognitive difficulties after COVID-19. It involves an online program called CO-OP (Cognitive Orientation to daily Occupational Performance), designed to enhance daily activities and quality of life. Participants will be divided into two groups: one will engage in the CO-OP program, while the other will not receive active treatment. Suitable candidates for this trial have ongoing memory or concentration issues that began after a COVID-19 infection and seek to improve their daily task performance. As an unphased trial, this study provides a unique opportunity for participants to potentially enhance their daily lives through innovative treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It might be best to discuss this with the trial coordinators or your doctor.
What prior data suggests that CO-OP Procedures are safe for individuals with post-COVID syndrome?
A previous study found the CO-OP (Cognitive Orientation to daily Occupational Performance) method to be both helpful and well-received. It improved participants' performance in daily tasks and their satisfaction with those tasks, while also aiding mood and anxiety. However, the studies reviewed did not provide specific safety information about using CO-OP for post-COVID syndrome, leaving no direct evidence of harmful effects from CO-OP itself.
Generally, methods like CO-OP are non-invasive, meaning they don't involve surgery or entering the body. They focus on improving thinking and planning skills through practice and support. These treatments are usually easy for participants to handle. If CO-OP had major safety issues, researchers likely wouldn't use it in studies. So, even without detailed safety data, the nature of the treatment suggests it is safe for most people.12345Why are researchers excited about this trial?
Researchers are excited about the Cognitive Orientation to daily Occupational Performance (CO-OP) approach for Post-COVID Syndrome because it offers a unique, non-pharmacological method to address cognitive rehabilitation. Unlike standard treatments that might focus on medication or general cognitive exercises, CO-OP is a tailored strategy that helps individuals develop personalized skills to improve their daily functioning. This method is delivered remotely, making it accessible and convenient for participants, especially those who may still be experiencing mobility issues or prefer at-home care. By focusing on practical, goal-oriented tasks, CO-OP has the potential to provide significant, tangible benefits in daily life activities for those recovering from the cognitive impacts of COVID-19.
What evidence suggests that CO-OP Procedures could be effective for post-COVID syndrome?
Research has shown that the CO-OP (Cognitive Orientation to daily Occupational Performance) approach, which participants in this trial may receive, can enhance thinking skills in individuals with post-COVID syndrome. A similar method, cognitive remediation therapy, has effectively improved skills such as clear speech and task planning. Participants in programs like CO-OP have reported better cognitive abilities and improved daily performance. Studies also suggest that rehabilitation strategies can help manage long COVID symptoms, including mental and physical health issues. This evidence indicates that CO-OP could benefit those experiencing cognitive difficulties after COVID-19.12367
Who Is on the Research Team?
Anna E Boone, PhD, OTR/L
Principal Investigator
University of Missouri Occupational Therapy
Are You a Good Fit for This Trial?
This trial is for individuals who have had COVID-19 and are struggling with cognitive issues at least 6 weeks after infection. Participants should be able to set personal goals, speak English fluently, give informed consent electronically, and have a past diagnosis of COVID-19. People with severe depression, untreated sleep apnea, prior cancer treatment, serious neurological or psychiatric conditions, or signs of dementia are not eligible.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the CO-OP intervention remotely via Zoom, with one session per week over the course of 10 weeks
Control
Inactive control group receives one session per week over the course of 10 weeks, delivered remotely via Zoom
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments conducted at the end of the study
What Are the Treatments Tested in This Trial?
Interventions
- CO-OP Procedures
- Inactive Control Group
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Missouri-Columbia
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator